mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-06-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-0326PMID 27342399PMCID PMC5161706
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs.

  2016cited by this paper
• Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies.

  2015cited by this paper
• Characterization of the metastatic phenotype of a panel of established osteosarcoma cells

  2015cited by this paper
• Stress-mediated translational control in cancer cells.

  2015cited by this paper
• Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma

  2014cited by this paper
• Translation factors and ribosomal proteins control tumor onset and progression: how?

  2014cited by this paper
• Translational reprogramming in cellular stress response

  2014cited by this paper
• Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

  2014cited by this paper
• Origins of metastatic traits.

  2013cited by this paper
• Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

  2013cited by this paper
• The mechanisms of Hedgehog signalling and its roles in development and disease

  2013cited by this paper
• The mTOR Signalling Pathway in Human Cancer

  2012cited by this paper
• Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma.

  2012cited by this paper
• Apoptosis resistance and PKC signaling: distinguishing features of high and low metastatic cells.

  2012cited by this paper
• Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

  2012cited by this paper
• The ezrin metastatic phenotype is associated with the initiation of protein translation.

  2012cited by this paper
• ViennaRNA Package 2.0

  2011cited by this paper
• Evaluation of eIF4E Expression in an Osteosarcoma-Specific Tissue Microarray

  2011cited by this paper
• Modeling metastasis biology and therapy in real time in the mouse lung.

  2010cited by this paper
• Osteosarcoma: a review of diagnosis, management, and treatment strategies.

  2010cited by this paper
• mTOR signaling at a glance

  2009cited by this paper
• The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC

  2009cited by this paper
• Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

  2008cited by this paper
• Preclinical studies of treosulfan demonstrate potent activity in Ewing’s sarcoma

  2008cited by this paper
• Labeling, detection and identification of newly synthesized proteomes with bioorthogonal non-canonical amino-acid tagging

  2007influential reference
• Regulation of cap-dependent translation by eIF4E inhibitory proteins

  2005cited by this paper
• The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis

  2004cited by this paper
• Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs

  2004cited by this paper
• An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential

  2004cited by this paper
• A Novel Function of the MA-3 Domains in Transformation and Translation Suppressor Pdcd4 Is Essential for Its Binding to Eukaryotic Translation Initiation Factor 4A

  2004cited by this paper
• Metastasis: Dissemination and growth of cancer cells in metastatic sites

  2002cited by this paper
• Regulation of protein synthesis by mRNA structure

  1994influential reference
• Structural features in eukaryotic mRNAs that modulate the initiation of translation.

  1991cited by this paper

• Identification of hub genes related to metastasis and prognosis of osteosarcoma and establishment of a prognostic model with bioinformatic methods

  2024cites this paper
• Disrupting YAP1-mediated glutamine metabolism induces synthetic lethality alongside ODC1 inhibition in osteosarcoma

  2024cites this paper
• Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis

  2024cites this paper
• Primary Bone Tumors and Breast Cancer-Induced Bone Metastases: In Vivo Animal Models and New Alternative Approaches

  2024cites this paper
• Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials.

  2024cites this paper
• Review: The PI3K-AKT-mTOR signal transduction pathway in canine cancer

  2023cites this paper
• Genomic and proteomic profiling of osteosarcoma

  2022cites this paper
• Osteosarcoma

  2022cites this paper
• Proteomic Assessment of Extracellular Vesicles from Canine Tissue Explants as a Pipeline to Identify Molecular Targets in Osteosarcoma: PSMD14/Rpn11 as a Proof of Principle

  2022cites this paper
• Recent and Ongoing Research into Metastatic Osteosarcoma Treatments

  2022cites this paper
• Compound Library Screening for Synergistic Drug Combinations: mTOR Inhibitor and Proteasome Inhibitor Effective Against Osteosarcoma Cells

  2022cites this paper
• Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment

  2022cites this paper
• Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.

  2021cites this paper
• Osteosarcoma and Metastasis

  2021cites this paper
• Impact of limb amputation and cisplatin chemotherapy on metastatic progression in mouse models of osteosarcoma

  2021cites this paper
• C3AR1 mRNA as a Potential Therapeutic Target Associates With Clinical Outcomes and Tumor Microenvironment in Osteosarcoma

  2021cites this paper
• PTHR1 in osteosarcoma: Specific molecular mechanisms and comprehensive functional perspective

  2021cites this paper
• Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

  2021influential citation
• Novel role of the dietary flavonoid fisetin in suppressing rRNA biogenesis

  2021cites this paper
• Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression

  2020cites this paper
• Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma.

  2020cites this paper
• Lkb1 deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation

  2019cites this paper
• [Role of mammalian target of rapamycin activation in menthol-induced expressions of airway inflammation-related factors in human bronchial epithelial cells in vitro].

  2019cites this paper
• Tegavivint and the β-catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.

  2019cites this paper
• Osteosarcoma: Accelerating Progress Makes for a Hopeful Future

  2018cites this paper
• Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay.

  2018cites this paper